MA26702A1 - Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation - Google Patents

Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation

Info

Publication number
MA26702A1
MA26702A1 MA25827A MA25827A MA26702A1 MA 26702 A1 MA26702 A1 MA 26702A1 MA 25827 A MA25827 A MA 25827A MA 25827 A MA25827 A MA 25827A MA 26702 A1 MA26702 A1 MA 26702A1
Authority
MA
Morocco
Prior art keywords
migraine
treatment
preparation
pharmaceutical compositions
metoclopramide
Prior art date
Application number
MA25827A
Other languages
English (en)
Inventor
Harry Sands Georges
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26702A1 publication Critical patent/MA26702A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

métoclopramide sont associés dans l'organisme d'un mammifère souffrant de migraine. 15. Procédé pour la production d'une composition pharmaceutique destinée au traitement de la migraine suivant les revendications 12 et 14, caractérisé en ce qu'il comprend l'association d'élétriptan, de métoclopramide et d'un support pharmaceutiquement acceptable. Compositions pharmaceutiques pour le traitement de la migraine, et procédé pour leur préparation La présente invention concerne une composition pharmaceutique comprenant du métoclopramide, un agoniste des récepteurs 5HT1 et un support pharmaceutiquement acceptable. Elle concerne également un procédé pour sa préparation. Application : utilisation de cette composition pharmaceutique pour le traitement de la migraine chez un mammifère.
MA25827A 1998-10-30 1999-10-27 Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation MA26702A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30

Publications (1)

Publication Number Publication Date
MA26702A1 true MA26702A1 (fr) 2004-12-20

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25827A MA26702A1 (fr) 1998-10-30 1999-10-27 Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation

Country Status (34)

Country Link
US (2) US6255334B1 (fr)
EP (1) EP1126840A1 (fr)
JP (1) JP2002528497A (fr)
KR (1) KR20010089363A (fr)
CN (1) CN1325304A (fr)
AP (1) AP2001002129A0 (fr)
AR (1) AR019246A1 (fr)
AU (1) AU5994799A (fr)
BG (1) BG105534A (fr)
BR (1) BR9914901A (fr)
CA (1) CA2348543A1 (fr)
CO (1) CO4950530A1 (fr)
CZ (1) CZ20011468A3 (fr)
EA (1) EA200100284A1 (fr)
EE (1) EE200100243A (fr)
GT (1) GT199900189A (fr)
HK (1) HK1040929A1 (fr)
HR (1) HRP20010298A2 (fr)
HU (1) HUP0104696A3 (fr)
ID (1) ID28291A (fr)
IL (1) IL141957A0 (fr)
IS (1) IS5898A (fr)
MA (1) MA26702A1 (fr)
NO (1) NO20012013L (fr)
OA (1) OA11669A (fr)
PA (1) PA8484801A1 (fr)
PE (1) PE20001284A1 (fr)
PL (1) PL347541A1 (fr)
SK (1) SK5522001A3 (fr)
TN (1) TNSN99203A1 (fr)
TR (1) TR200101174T2 (fr)
TW (1) TW524692B (fr)
WO (1) WO2000025778A1 (fr)
ZA (1) ZA200103322B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
JP4357842B2 (ja) * 2001-05-24 2009-11-04 アレックザ ファーマシューティカルズ， インコーポレイテッド 所定の吸入ルートによるアルプラゾラム、エスタゾラム、ミダゾラムまたはトリアゾラムの送出
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
CA2446904A1 (fr) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Administration d'esters medicamenteux par inhalation
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
EP1446102A1 (fr) 2001-11-21 2004-08-18 Alexza Molecular Delivery Corporation Delivrance de cafeine par voie inhalee
CA2483687A1 (fr) 2002-05-13 2003-11-20 Alexza Pharmaceuticals, Inc. Distribution de medicament a base d'amines par voie d'inhalation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
MXPA05005611A (es) 2002-11-26 2005-07-27 Alexza Pharmaceuticals Inc Uso de loxapina y amoxapina para la fabricacion de un medicamento para el tratamiento del dolor.
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
CA2526478A1 (fr) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Procede de regulation thermique uniforme d'un substrat ; unite de chauffage integree et unite d'administration de medicaments recourant a ce procede
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
ATE489138T1 (de) 2005-04-13 2010-12-15 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität
ZA200809659B (en) * 2006-04-13 2010-03-31 Neuraxon Inc 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
US20090163451A1 (en) * 2007-11-16 2009-06-25 Frank Porreca Methods for treating visceral pain
WO2009062318A1 (fr) * 2007-11-16 2009-05-22 Neuraxon, Inc. Composés d'indole 3,5-substitués ayant une activité d'inhibition de la réabsorption de la nos et de la noradrénaline
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine
MX2020007997A (es) 2018-02-02 2020-12-03 Alexza Pharmaceuticals Inc Dispositivo electrico de aerosol de condensacion.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
US20010020036A1 (en) 2001-09-06
US6255334B1 (en) 2001-07-03
PA8484801A1 (es) 2000-09-29
TNSN99203A1 (fr) 2005-11-10
CZ20011468A3 (cs) 2002-04-17
EA200100284A1 (ru) 2001-10-22
TR200101174T2 (tr) 2001-10-22
HUP0104696A3 (en) 2003-05-28
ID28291A (id) 2001-05-10
CN1325304A (zh) 2001-12-05
EP1126840A1 (fr) 2001-08-29
CA2348543A1 (fr) 2000-05-11
PE20001284A1 (es) 2000-11-22
HRP20010298A2 (en) 2002-06-30
WO2000025778A1 (fr) 2000-05-11
CO4950530A1 (es) 2000-09-01
TW524692B (en) 2003-03-21
JP2002528497A (ja) 2002-09-03
NO20012013D0 (no) 2001-04-24
IL141957A0 (en) 2002-03-10
NO20012013L (no) 2001-04-24
BR9914901A (pt) 2001-07-17
AU5994799A (en) 2000-05-22
AP2001002129A0 (en) 2001-06-30
GT199900189A (es) 2001-04-21
KR20010089363A (ko) 2001-10-06
OA11669A (en) 2005-01-05
HUP0104696A2 (hu) 2002-05-29
SK5522001A3 (en) 2002-05-09
PL347541A1 (en) 2002-04-08
IS5898A (is) 2001-03-16
HK1040929A1 (zh) 2002-06-28
BG105534A (en) 2001-12-29
EE200100243A (et) 2002-12-16
ZA200103322B (en) 2002-06-10
AR019246A1 (es) 2001-12-26

Similar Documents

Publication Publication Date Title
TNSN99203A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
DZ2639A1 (fr) Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
CA2324904A1 (fr) Composition hormonale topique a effet systemique
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
EP0738152A4 (fr) Agents de chimioprevention ou de chimiotherapie du cancer du colon a base de derives de l'acide 2-hydroxy-5-phenylazobenzoique
NZ509762A (en) 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
DZ2948A1 (fr) Dérivé d'indole nouveau, procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA24704A1 (fr) Formulations nouvelles de paroxetine et procede pour leur preparation
GB2266665B (en) 5-HT1-like receptor agonist for rectal administration
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
CA2377519A1 (fr) Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau
EA200400302A1 (ru) Способ лечения первичной бессонницы
DZ2954A1 (fr) Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
TNSN98124A1 (fr) Compositions de sertraline solubilisee